The value and safety of trilaciclib in combination with first-line chemotherapy and immunotherapy for extensive-stage SCLC.

IF 2.3 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2025-09-11 DOI:10.1080/1750743X.2025.2559578

Shuo He, Yunchuan Sun, Li Xiao, Hongling Lu, Xiaoming Yin, Jixnxi Zhou, Yingnan Zhou, Shengtan Zhang

{"title":"The value and safety of trilaciclib in combination with first-line chemotherapy and immunotherapy for extensive-stage SCLC.","authors":"Shuo He, Yunchuan Sun, Li Xiao, Hongling Lu, Xiaoming Yin, Jixnxi Zhou, Yingnan Zhou, Shengtan Zhang","doi":"10.1080/1750743X.2025.2559578","DOIUrl":null,"url":null,"abstract":"Aims: To evaluate the myeloprotective effects, safety, and survival outcomes of trilaciclib in first-line chemotherapy for extensive-stage small cell lung cancer (ES-SCLC) in China.Methods: A single-center, retrospective study was conducted with 120 ES-SCLC patients receiving chemotherapy plus immunotherapy between January 2020 and January 2024. Patients were divided into a trilaciclib group (n = 60) and a control group (n = 60). The groups were compared for chemotherapy-related adverse effects, efficacy (ORR, DCR), and survival (PFS, OS).Results: Trilaciclib significantly reduced the incidence of grade 3-4 neutropenia (18.3% vs. 66.7%, p < 0.001), grade ≥ 3 anemia (13.3% vs. 33.3%, p = 0.010), and thrombocytopenia (10.0% vs. 26.7%, p = 0.018). Median PFS was significantly longer in the trilaciclib group (6.2 vs. 4.7 months, p = 0.0139, HR = 0.6238, 95%CI 0.4474-0.9826), but no significant difference was observed in OS (15.6 vs. 13.8 months, p = 0.2399, HR = 0.8053, 95%CI 0.5577-1.163). The ORR was similar between the two groups (73.3% vs. 63.3%, p = 0.239).Conclusions: Trilaciclib demonstrates myeloprotective benefits in first-line treatment of ES-SCLC, with significant reductions in chemotherapy-related myelosuppression and improvements in treatment adherence. Although PFS was improved, no significant differences in OS or ORR were observed, indicating the need for further research with larger sample sizes to confirm its clinical efficacy.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.3000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2025.2559578","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: To evaluate the myeloprotective effects, safety, and survival outcomes of trilaciclib in first-line chemotherapy for extensive-stage small cell lung cancer (ES-SCLC) in China.

Methods: A single-center, retrospective study was conducted with 120 ES-SCLC patients receiving chemotherapy plus immunotherapy between January 2020 and January 2024. Patients were divided into a trilaciclib group (n = 60) and a control group (n = 60). The groups were compared for chemotherapy-related adverse effects, efficacy (ORR, DCR), and survival (PFS, OS).

Results: Trilaciclib significantly reduced the incidence of grade 3-4 neutropenia (18.3% vs. 66.7%, p < 0.001), grade ≥ 3 anemia (13.3% vs. 33.3%, p = 0.010), and thrombocytopenia (10.0% vs. 26.7%, p = 0.018). Median PFS was significantly longer in the trilaciclib group (6.2 vs. 4.7 months, p = 0.0139, HR = 0.6238, 95%CI 0.4474-0.9826), but no significant difference was observed in OS (15.6 vs. 13.8 months, p = 0.2399, HR = 0.8053, 95%CI 0.5577-1.163). The ORR was similar between the two groups (73.3% vs. 63.3%, p = 0.239).

Conclusions: Trilaciclib demonstrates myeloprotective benefits in first-line treatment of ES-SCLC, with significant reductions in chemotherapy-related myelosuppression and improvements in treatment adherence. Although PFS was improved, no significant differences in OS or ORR were observed, indicating the need for further research with larger sample sizes to confirm its clinical efficacy.

查看原文本刊更多论文

trilaciclib联合一线化疗和免疫治疗广泛期SCLC的价值和安全性。

目的：评价trilaciclib在中国广泛期小细胞肺癌（ES-SCLC）一线化疗中的骨髓保护作用、安全性和生存结局。方法：对2020年1月至2024年1月期间接受化疗加免疫治疗的120例ES-SCLC患者进行单中心回顾性研究。患者分为trilaciclib组（n = 60）和对照组（n = 60）。比较各组化疗相关不良反应、疗效（ORR、DCR）和生存（PFS、OS）。结果：Trilaciclib显著降低了3-4级中性粒细胞减少症（18.3% vs. 66.7%, p < 0.001）、≥3级贫血（13.3% vs. 33.3%, p = 0.010）和血小板减少症（10.0% vs. 26.7%, p = 0.018）的发生率。trilaciclib组的中位PFS明显更长（6.2个月vs 4.7个月，p = 0.0139, HR = 0.6238, 95%CI 0.4474-0.9826），但OS无显著差异（15.6个月vs 13.8个月，p = 0.2399, HR = 0.8053, 95%CI 0.5577-1.163）。两组的ORR相似（73.3% vs. 63.3%, p = 0.239）。结论：Trilaciclib在ES-SCLC的一线治疗中显示出骨髓保护作用，显著降低化疗相关的骨髓抑制，改善治疗依从性。虽然PFS有所改善，但OS和ORR无明显差异，需要进一步扩大样本量的研究来证实其临床疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.